Sign In
Buy THTX
$3.39
+0 (+0%)
At Close: Dec 24, 2025
MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, wishes to ad
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
09:57am, Friday, 11'th Apr 2025
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC (“Future Pak”) today announced that it has submitted two formal proposals since January to acquire all outstanding shares of common stock of Theratec
Theratechnologies Inc. (THTX) Q1 2025 Earnings Call Transcript
10:28am, Wednesday, 09'th Apr 2025
Theratechnologies Inc. (NASDAQ:THTX ) Q1 2025 Earnings Conference Call April 9, 2025 8:30 AM ET Company Participants Joanne Choi - Senior Director, Investor Relations Paul Levesque - President and Chi
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
07:30am, Wednesday, 09'th Apr 2025
MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reporte
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
04:30pm, Thursday, 03'rd Apr 2025
MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announc
New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a com
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
07:30am, Wednesday, 12'th Mar 2025
MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today present
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
07:30am, Wednesday, 12'th Mar 2025
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV
Theratechnologies Inc. (THTX) Q4 2024 Earnings Call Transcript
01:21pm, Wednesday, 26'th Feb 2025
Theratechnologies Inc. (NASDAQ:THTX ) Q4 2024 Earnings Conference Call February 26, 2024 8:30 AM ET Company Participants Joanne Choi - Senior Director, Investor Relations Paul Levesque - President & C
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
07:30am, Wednesday, 26'th Feb 2025
MONTREAL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commerc
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
07:30am, Friday, 14'th Feb 2025
MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commerc
Theratechnologies Resumes Distribution of EGRIFTA SV®
07:45pm, Thursday, 13'th Feb 2025
MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a specialty biopharmaceutical company focused on the commerc
Theratechnologies Provides Update on EGRIFTA SV® Supply
05:05pm, Thursday, 09'th Jan 2025
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and c
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
01:30pm, Wednesday, 18'th Dec 2024
MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and c
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
03:15pm, Tuesday, 10'th Dec 2024
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and c
